牛牛AI助理已提取核心訊息
On February 28, 2024, 180 Life Sciences Corp. reported the exercise of pre-funded warrants by a holder, resulting in the purchase of 64,684 shares of common stock at $0.0019 per share, amounting to $122.90 in cash. This transaction followed a 1-for-19 reverse stock split effective on the same date, as previously disclosed in a Current Report on Form 8-K filed with the SEC. The shares from the warrant exercise are to be issued and were exempt from registration under Section 4(a)(2) of the Securities Act, with their resale registered under a registration statement declared effective under the Securities Act. Post-issuance, the company's issued and outstanding common stock will total approximately 652,292 shares, not accounting for rounding from the reverse stock split. The report was signed by CEO James N. Woody, M.D., Ph.D., on March 1, 2024.
On February 28, 2024, 180 Life Sciences Corp. reported the exercise of pre-funded warrants by a holder, resulting in the purchase of 64,684 shares of common stock at $0.0019 per share, amounting to $122.90 in cash. This transaction followed a 1-for-19 reverse stock split effective on the same date, as previously disclosed in a Current Report on Form 8-K filed with the SEC. The shares from the warrant exercise are to be issued and were exempt from registration under Section 4(a)(2) of the Securities Act, with their resale registered under a registration statement declared effective under the Securities Act. Post-issuance, the company's issued and outstanding common stock will total approximately 652,292 shares, not accounting for rounding from the reverse stock split. The report was signed by CEO James N. Woody, M.D., Ph.D., on March 1, 2024.
2024年2月28日，180生命科學公司報告稱，持有人行使了預先注資的認股權證，結果以每股0.0019美元的價格購買了64,684股普通股，總額爲122.90美元的現金。正如先前在向美國證券交易委員會提交的8-K表最新報告中披露的那樣，該交易是在同日生效的1比19的反向股票拆分之後進行的。根據《證券法》第4（a）（2）條，認股權證行使中的股票將發行且免於註冊，其轉售是根據證券法宣佈生效的註冊聲明進行的。發行後，該公司的已發行和流通普通股總額將約爲652,292股，不包括反向股票拆分的四捨五入。該報告由首席執行官詹姆斯·伍迪醫學博士、博士於2024年3月1日簽署。
2024年2月28日，180生命科學公司報告稱，持有人行使了預先注資的認股權證，結果以每股0.0019美元的價格購買了64,684股普通股，總額爲122.90美元的現金。正如先前在向美國證券交易委員會提交的8-K表最新報告中披露的那樣，該交易是在同日生效的1比19的反向股票拆分之後進行的。根據《證券法》第4（a）（2）條，認股權證行使中的股票將發行且免於註冊，其轉售是根據證券法宣佈生效的註冊聲明進行的。發行後，該公司的已發行和流通普通股總額將約爲652,292股，不包括反向股票拆分的四捨五入。該報告由首席執行官詹姆斯·伍迪醫學博士、博士於2024年3月1日簽署。
有用
沒用
